

899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002

October 7, 2021

9:30 am

OPEN SESSION AGENDA
(VIA ZOOM MEETING DUE TO THE COVID-19 PUBLIC HEALTH EMERGENCY)

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

CALL TO ORDER:

PRESIDING:

BOARD MEMBERSHIP/ATTENDANCE:

BOARD MEMBERS:		
	DR. TAMARA McCANTS, PHARM.D. R.PH CHAIRPERSON	
	MR. ALAN FRIEDMAN, R.PH, VICE CHAIRPERSON	
	DR. BENJAMIN MILES, PHARM.D. R.PH	
	DR. ASHLEE BOW, PHARM.D. R.PH	
	DR. ALLISON HILL, PHARM.D. R.PH	
	MR. GREGORY CENDANA, CONSUMER MEMBER	
STAFF:	DR. JUSTIN ORTIQUE, INTERIM EXECUTIVE DIRECTOR	
	KARIN BARRON, HEALTH LICENSING SPECIALIST	
	LUANNE GREENAWAY, PROGRAM SPECIALIST	
	COUNTEE GILLIAM, BOARD INVESTIGATOR	
LEGAL STAFF:	CARLA WILLIAMS, SENIOR ASSISTANT GENERAL COUNSEL	
VISITORS:		

Open Session Agenda

Quorum:

Introduction:		
1007-O-01	<u>Approval of the Open Session Meeting Minutes for</u> August 5, 2021 September 2, 2021	
<u>Consent Agenda</u>	None	
<u>Chairperson Report</u>	<u>Interprofessional Workgroup</u>	Dr. Tamara McCants
<u>Executive Director Report</u>	<ul style="list-style-type: none"> ▪ Statistical Report on Pharmacy professionals in the District of Columbia ▪ Prescription Drug Monitoring Program Updates ▪ DCRx (DC Center for Rational Prescribing) 	Dr. Justin Ortique
<u>Senior Assistant General Counsel Report</u>		
1007-O-02	<u>Notice of Emergency And Proposed Rulemaking</u> (a) Continuing Education For Sars-Cov-2 Vaccine Counseling	Ms. Carla Williams
<u>Subcommittee Reports</u>		
1007-O-03	<u>Legislative and Regulatory Subcommittee Report</u>	Mr. Alan Friedman
1007-O-04	<u>Communications Subcommittee Report</u>	Dr. Ashlee Bow
<u>Matters for Consideration</u>		
1007-O-05	<u>Administration of Monoclonal Antibodies by Pharmacy Students Inquiry</u> <u>Bonnie Levin, PharmD, MBA, FASHP</u> <u>AVP, Pharmacy Services, MedStar Health</u> (a) Email Communication (b) Ninth Amendment to Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19 (c) Expanding Access to COVID-19 Therapeutics HHS PREP Act Declaration: 9th Amendment	

<p>NABP E-Newsletter</p>	<p><u>September 22, 2021</u></p> <p>Help Educate Patients on the Importance of Buying Medication From Verified Sites</p> <p>Final Guidance Released on Biosimilar Development and BPCI Act</p> <p>DEA to Hold Next Drug Take Back Day on October 23rd</p> <p>Toolkit Available to Help Educate Older Adults on Safe Acetaminophen Use</p> <p>Pharmacists in Two New York Counties Required to Include Safe Disposal Kits With Every Opioid Prescription</p> <p>FDA Continues Collaboration With Drug Compounders Through Compounding Quality Center of Excellence</p> <p>SAMHSA Awards More Than \$123 Million to Combat Opioid Epidemic</p> <p><u>September 29, 2021</u></p> <p>COVID-19 Booster Authorized for Certain Groups</p> <p>NABP Joins Other Regulatory Associations In Launching Opioid Regulatory Collaborative</p> <p>Montana Board of Pharmacy Reinstates Emergency Rule to Help Pharmacists Oversee, Administer Vaccinations</p> <p>DEA Warns of Increase in Counterfeit Pills Containing Fentanyl</p> <p>Recall Issued for Cefazolin Injection Products Due to a Lack of Sterility Assurance</p> <p>DEA Announces Virtual Red Ribbon Rally October 5 to Help Promote Drug-Free Lifestyles</p> <p>Celebrate World Heart Day by Raising Awareness on How Substandard, Falsified Medicines Can Endanger Cardiac Patients</p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link:</p> <p>https://nabp.pharmacy/newsroom/news/.</p>	<p>Dr. Tamara McCants</p>
<p><u>Comments from the Public</u></p>		

<p><u>Motion to Adjourn the Open Session</u></p>	<p>“Madam Board Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14).” ROLL CALL VOTE</p>	
---	---	--

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at __:__ AM.

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.